dc.contributor | Universitat Ramon Llull. IQS | |
dc.contributor.author | Sánchez García, David | |
dc.contributor.author | Borrós i Gómez, Salvador | |
dc.contributor.author | Fornaguera Puigvert, Cristina | |
dc.contributor.author | Martínez Edo, Gabriel | |
dc.date.accessioned | 2021-07-25T16:17:25Z | |
dc.date.accessioned | 2023-07-13T05:45:44Z | |
dc.date.available | 2021-07-25T16:17:25Z | |
dc.date.available | 2023-07-13T05:45:44Z | |
dc.date.issued | 2020-11 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14342/1108 | |
dc.description.abstract | A pH-triggered mesoporous silica nanoparticle (MSN)-based nano-vehicle for the dual delivery of doxorubicin (DOX)/camptothecin-PEG (CPT-PEG) has been prepared. To enhance its selectivity, the nanoparticles were decorated with glycyrrhetinic acid (GA) to target HepG2 cells. The highly insoluble CPT was derivatized with a reductive-cleavable PEG chain to improve its loading within the MSN. The preparation of these particles consisted of four steps. First, CPT-PEG was loaded within the pores of the MSN. Then, dihydrazide polyethylene glycol chains were introduced onto the surface of an aldehyde-functionalized MSN by means of a hydrazone bond. Afterwards, DOX was covalently attached to the other end of the dihydrazide polyethylene glycol chains. Finally, the resulting nanoparticles were decorated with GA by formation of an imine bond between the amino group of DOX and a benzaldehyde-GA derivative. The system was stable at physiological conditions and the release of both drugs was negligible. However, at acidic pH, a burst release of DOX and a gradual release of CPT-PEG takes place. GA-decorated drug delivery systems (DDS) selectively internalizes into HepG2. In vitro tests demonstrated that this system shows a great cytotoxicity towards HepG2 cells. Furthermore, glutathione cleavage of CPT prodrug assures the formation of free CPT leading to a synergistic effect in combination with DOX. | eng |
dc.format.extent | 17 p. | cat |
dc.language.iso | eng | cat |
dc.publisher | MDPI | cat |
dc.relation.ispartof | Pharmaceutics. Vol.12, n.11 (2020), 1048 | cat |
dc.rights | Attribution 4.0 International | |
dc.rights | © L'autor/a | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | RECERCAT (Dipòsit de la Recerca de Catalunya) | |
dc.subject.other | Nanopartícules | cat |
dc.subject.other | Doxorubicina | cat |
dc.subject.other | Medicaments | cat |
dc.subject.other | Càncer | cat |
dc.subject.other | Mesoporous silica nanoparticles | cat |
dc.subject.other | Dual release | cat |
dc.subject.other | Doxorubicin | cat |
dc.subject.other | Camptothecin | cat |
dc.subject.other | Anticancer drugs | cat |
dc.subject.other | Combination therapy | cat |
dc.subject.other | Targeting systems | cat |
dc.title | Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles for the co-delivery of DOX/CPT-PEG for targeting HepG2 cells | cat |
dc.type | info:eu-repo/semantics/article | cat |
dc.type | info:eu-repo/semantics/publishedVersion | cat |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | cat |
dc.subject.udc | 539 | |
dc.subject.udc | 616 | |
dc.identifier.doi | https://doi.org/10.3390/pharmaceutics12111048 | cat |
dc.relation.projectID | info:eu-repo/grantAgreement/MCIU/PN I+D/RTI2018-094734-B-C22 | cat |
dc.relation.projectID | info:eu-repo/grantAgreement/SUR del DEC/SGR/2017-SGR-01559 | cat |